GlassScriptPhysician profile
Tien-Chun Chen
NPI 1396005450
$13,941.32
in general payments reported to CMS, 2019-2025
26 companies · $1,431 in 2025
The $1,431 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,448 · 2020: $1,509 · 2021: $1,594 · 2022: $1,201 · 2023: $1,426 · 2024: $1,331 · 2025: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,015 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,014.87 |
| Education | $173.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,160.82 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Gilead Sciences, INC. | $3,829.44 | 2019-2025 | |
| Janssen Biotech, INC. | $988.67 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $813.75 | 2019-2025 | Xifaxan, Trulance |
| Ironwood Pharmaceuticals, INC | $678.74 | 2019-2023 | Linzess |
| Qol Medical, LLC | $554.73 | 2020-2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $380.64 | 2019-2024 | Ocaliva |
| Ardelyx, INC. | $352.21 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $319.70 | 2020-2024 | Entyvio |
| Phathom Pharmaceuticals, INC. | $246.89 | 2023-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $221.19 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $217.54 | 2019 | |
| Merck Sharp & Dohme LLC | $205.33 | 2020-2024 | Dificid, Zinplava |
| Celgene Corporation | $140.26 | 2021-2024 | Zeposia |
| Allergan, INC. | $136.06 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $124.94 | 2019 | |
| Madrigal Pharmaceuticals | $122.87 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $122.47 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $119.93 | 2021 | |
| Redhill Biopharma INC. | $89.65 | 2022-2023 | Talicia, Movantik, Aemcolo |
| Nestle Healthcare Nutrition INC. | $24.97 | 2021 | |
| Pfizer INC. | $23.32 | 2025 | |
| Vivus LLC | $20.25 | 2022 | |
| W. L. Gore & Associates, INC. | $17.10 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $16.65 | 2025 | Iqirvo |
| Erbe USA INC | $13.20 | 2023 | Erbe Vio3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tien-Chun Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.